|
|
|
|
| LEADER |
01457nam a2200277 u 4500 |
| 001 |
EB001840069 |
| 003 |
EBX01000000000000001004058 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Aripiprazole for patients with bipolar disorder
|h Elektronische Ressource
|b a review of the clinical effectiveness, cost-effectiveness, and guidelines
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 25 May 2016
|
| 300 |
|
|
|a 1 PDF file (20 pages)
|b illustration
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Aripiprazole / therapeutic use
|
| 653 |
|
|
|a Guidelines as Topic
|
| 653 |
|
|
|a Bipolar Disorder / drug therapy
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 500 |
|
|
|a "CADTH Rapid Response Service."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK368301
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This Rapid Response report aims to review the clinical and cost-effectiveness of aripiprazole for patients with bipolar disorder. Guidelines associated with the use of aripiprazole for patients with bipolar disorder will also be examined
|